Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia

Journal of Hospital Medicine

Volumn 5, Issue 9, 2010, Pages 528-534

  Taneja, Charu ^a   Haque, Nadia ^b   Oster, Gerry ^a   Shorr, Andrew F ^c   Zilber, Sophia ^a   Kyan, Paola Osaki ^b   Reyes, Katherine C ^b   Moore, Carol ^b   Spalding, James ^d   Kothari, Smita ^d   Zervos, Marcus ^b  

^a POLICY ANALYSIS INC PAI   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Clinical acquired; Community acquired; Methicillin resistant; Methicillin susceptible; Staphylococcus aureus pneumonia

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; LINEZOLID; TIGECYCLINE; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; TEACHING HOSPITAL; UNITED STATES; URBAN AREA;

ADOLESCENT; ADULT; AGED; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONIA, STAPHYLOCOCCAL; RETROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS; UNITED STATES; YOUNG ADULT;

EID: 78650337422     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.704     Document Type: Article

References (33)

1. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis. 1998; 26: 1179-1181.
2. Lowry F. Staphylococcus aureus infections. N Engl J Med. 1998; 339: 520-532.
3. Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med. 2006; 144: 368-370.
4. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006; 130: 947-955.
5. Schwarzmann SW, Adler JL, Sullivan RJ, Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med. 1971; 127: 1037-1041.
6. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006; 12: 894-899.
7. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. Morb Mortal Wkly Rep. 2007; 56: 325-329.
8. Vardakas KZ, Matthaiou DK, Falagas ME. Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J. 2009; 34: 1148-1158.
9. Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med. 2009; 53: 358-365.
10. Howden BP, Ward PB, Charles PGP, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004; 38: 521-528.
11. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42: 2398-2402.
12. Soriano AF, Marco JA, Martinez E, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of Methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46: 193-200.
13. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med. 2006; 166: 2138-2144.
14. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax. 2003; 58(5): 377-382.
15. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 8th ed. CLSI document M07-A8 2008;29(2):1-65. Available at.
16. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol. 2007; 45: 329-332.
17. Singh A, Goering RV, Simjee S, Foley SL, Zervos MJ. Application of molecular techniques to the study of hospital infection. Clin Microbiol Rev. 2006; 19: 512-530.
18. Selvey LA, Whitby M, Johnson B. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: Is it any worse than nosocomial methicillin-sensitive Staphylococcus aureus bacteremia? Infect Control Hosp Epidemiol. 2000; 21: 645-648.
19. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2005; 52: 113-122.
20. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis. 2003; 36: 53-59.
21. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med. 1994; 150: 1545-1549.
22. Zahar JR, Clec'h C, Tafflet M, et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis. 2005; 41: 1224-1231.
23. Tenover FC, McDougal LK, Goering RV, et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol. 2006; 44: 108-111.
24. Morgan M. Staphylococcus aureus, Panton-Valentine leukocidin, and necrotising pneumonia. BMJ. 2005; 331: 793-794.
25. Monaco M, Antonucci R, Palange P, et al. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Emerg Infect Dis. 2005; 11: 1647-1648.
26. Peleg AY, Munckhof WJ. Fatal necrotizing pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus (MRSA). Med J Aust. 2004; 181: 228-229.
27. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: Importance of treatment with antimicrobials inhibiting exotoxin production. Chest. 2005; 128: 2732-2738.
28. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005; 40: 100-107.
29. Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007; 315: 1130-1133.
30. Gillet Y, Issartel P, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet. 2002; 359: 753-759.
31. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004; 38: 1700-1705.
32. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44(Suppl 2): S27-S72.
33. Zilberberg MD, Shorr AF, Micek ST, et al. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single center experience. Chest. 2008; 134: 963-968.